DNLI
Price
$19.78
Change
-$0.43 (-2.13%)
Updated
Feb 29, 6:59 PM EST
62 days until earnings call
EDIT
Price
$10.06
Change
-$1.01 (-9.12%)
Updated
Feb 29, 6:59 PM EST
61 days until earnings call
Ad is loading...

Compare predictions DNLI vs EDIT

Header iconDNLI vs EDIT Comparison
Open Charts DNLI vs EDITBanner chart's image
Denali Therapeutics
Price$19.78
Change-$0.43 (-2.13%)
Volume$899.78K
CapitalizationN/A
Editas Medicine
Price$10.06
Change-$1.01 (-9.12%)
Volume$2.42M
CapitalizationN/A
View a ticker or compare two or three
DNLI vs EDIT Comparison Chart

Loading...

DNLIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
EDITDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
DNLI vs. EDIT commentary
Mar 01, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a StrongSell and EDIT is a Sell.

COMPARISON
Comparison
Mar 01, 2024
Stock price -- (DNLI: $19.77 vs. EDIT: $10.06)
Brand notoriety: DNLI and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 92% vs. EDIT: 228%
Market capitalization -- DNLI: $2.73B vs. EDIT: $821.64M
DNLI [@Biotechnology] is valued at $2.73B. EDIT’s [@Biotechnology] market capitalization is $821.64M. The market cap for tickers in the [@Biotechnology] industry ranges from $541.24B to $0. The average market capitalization across the [@Biotechnology] industry is $2.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while EDIT’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 4 bearish.
  • EDIT’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than EDIT.

Price Growth

DNLI (@Biotechnology) experienced а +17.47% price change this week, while EDIT (@Biotechnology) price change was +26.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.64%. For the same industry, the average monthly price growth was +16.56%, and the average quarterly price growth was +43.85%.

Reported Earning Dates

DNLI is expected to report earnings on May 02, 2024.

EDIT is expected to report earnings on May 01, 2024.

Industries' Descriptions

@Biotechnology (+5.64% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for DNLI with price predictions.
OPEN
A.I.dvisor published
a Summary for EDIT with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
DNLI($2.73B) has a higher market cap than EDIT($822M). EDIT YTD gains are higher at: -0.691 vs. DNLI (-7.875). DNLI has higher annual earnings (EBITDA): -150.83M vs. EDIT (-202.49M). DNLI has more cash in the bank: 1.11B vs. EDIT (350M). EDIT has less debt than DNLI: EDIT (34.6M) vs DNLI (53.9M). DNLI has higher revenues than EDIT: DNLI (341M) vs EDIT (24.6M).
DNLIEDITDNLI / EDIT
Capitalization2.73B822M332%
EBITDA-150.83M-202.49M74%
Gain YTD-7.875-0.6911,140%
P/E Ratio62.89N/A-
Revenue341M24.6M1,386%
Total Cash1.11B350M317%
Total Debt53.9M34.6M156%
FUNDAMENTALS RATINGS
DNLI vs EDIT: Fundamental Ratings
DNLI
EDIT
OUTLOOK RATING
1..100
1119
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
34
Fair valued
PROFIT vs RISK RATING
1..100
95100
SMR RATING
1..100
9097
PRICE GROWTH RATING
1..100
5141
P/E GROWTH RATING
1..100
96100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for DNLI (81). This means that EDIT’s stock grew somewhat faster than DNLI’s over the last 12 months.

DNLI's Profit vs Risk Rating (95) in the Biotechnology industry is in the same range as EDIT (100). This means that DNLI’s stock grew similarly to EDIT’s over the last 12 months.

DNLI's SMR Rating (90) in the Biotechnology industry is in the same range as EDIT (97). This means that DNLI’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's Price Growth Rating (41) in the Biotechnology industry is in the same range as DNLI (51). This means that EDIT’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (96) in the Biotechnology industry is in the same range as EDIT (100). This means that DNLI’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIEDIT
RSI
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 8 days ago
79%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 8 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
74%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
83%
View a ticker or compare two or three
Ad is loading...
DNLIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
EDITDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FLVIX49.280.44
+0.90%
Fidelity Advisor Leveraged Co StkI
LONAX13.550.11
+0.82%
Longboard A
AALRX26.770.14
+0.53%
American Beacon Large Cap Value R6
HNVIX35.24N/A
N/A
Heartland Value Plus Institutional
AEGFX56.40-0.03
-0.05%
American Funds Europacific Growth F1

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been closely correlated with BEAM. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-2.18%
BEAM - DNLI
68%
Closely correlated
-9.45%
NTLA - DNLI
68%
Closely correlated
-2.07%
JANX - DNLI
62%
Loosely correlated
+3.77%
VCYT - DNLI
61%
Loosely correlated
-0.93%
EDIT - DNLI
59%
Loosely correlated
-9.12%
More

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been closely correlated with NTLA. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-9.12%
NTLA - EDIT
69%
Closely correlated
-2.07%
BEAM - EDIT
64%
Loosely correlated
-9.45%
VCYT - EDIT
56%
Loosely correlated
-0.93%
AXON - EDIT
52%
Loosely correlated
-0.62%
FOLD - EDIT
51%
Loosely correlated
-1.08%
More